Cardiac Biomarkers Market Report – Research, Industry Analysis Reports and Market Demands

Global Cardiac Biomarkers Market Insights, Forecast to 2025

Request for Sample of this report

Buy now

Table of Content

1 Study Coverage

1.1 Cardiac Biomarkers Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
- 1.4.1 Global Cardiac Biomarkers Market Size Growth Rate by Product
- 1.4.2 Troponin
- 1.4.3 CK-MB
- 1.4.4 Natriuretic Peptides - BNP and NT-proBNP
- 1.4.5 Myoglobin
- 1.4.6 Others
1.5 Market by End User
- 1.5.1 Global Cardiac Biomarkers Market Size Growth Rate by End User
- 1.5.2 Acute Coronary Syndrome
- 1.5.3 Myocardial Infarction
- 1.5.4 Congestive Heart Failure
- 1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary

2.1 Global Cardiac Biomarkers Market Size
- 2.1.1 Global Cardiac Biomarkers Revenue 2014-2025
- 2.1.2 Global Cardiac Biomarkers Sales 2014-2025
2.2 Cardiac Biomarkers Growth Rate by Regions
- 2.2.1 Global Cardiac Biomarkers Sales by Regions
- 2.2.2 Global Cardiac Biomarkers Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Cardiac Biomarkers Sales by Manufacturers
- 3.1.1 Cardiac Biomarkers Sales by Manufacturers
- 3.1.2 Cardiac Biomarkers Sales Market Share by Manufacturers
- 3.1.3 Global Cardiac Biomarkers Market Concentration Ratio (CR5 and HHI)
3.2 Cardiac Biomarkers Revenue by Manufacturers
- 3.2.1 Cardiac Biomarkers Revenue by Manufacturers (2014-2019)
- 3.2.2 Cardiac Biomarkers Revenue Share by Manufacturers (2014-2019)
3.3 Cardiac Biomarkers Price by Manufacturers
3.4 Cardiac Biomarkers Manufacturing Base Distribution, Product Types
- 3.4.1 Cardiac Biomarkers Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cardiac Biomarkers Product Type
- 3.4.3 Date of International Manufacturers Enter into Cardiac Biomarkers Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Cardiac Biomarkers Sales by Product
4.2 Global Cardiac Biomarkers Revenue by Product
4.3 Cardiac Biomarkers Price by Product

5 Breakdown Data by End User

5.1 Overview
5.2 Global Cardiac Biomarkers Breakdown Data by End User

6 North America

6.1 North America Cardiac Biomarkers by Countries
- 6.1.1 North America Cardiac Biomarkers Sales by Countries
- 6.1.2 North America Cardiac Biomarkers Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
6.2 North America Cardiac Biomarkers by Product
6.3 North America Cardiac Biomarkers by End User

7 Europe

7.1 Europe Cardiac Biomarkers by Countries
- 7.1.1 Europe Cardiac Biomarkers Sales by Countries
- 7.1.2 Europe Cardiac Biomarkers Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
7.2 Europe Cardiac Biomarkers by Product
7.3 Europe Cardiac Biomarkers by End User

8 Asia Pacific

8.1 Asia Pacific Cardiac Biomarkers by Countries
- 8.1.1 Asia Pacific Cardiac Biomarkers Sales by Countries
- 8.1.2 Asia Pacific Cardiac Biomarkers Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
8.2 Asia Pacific Cardiac Biomarkers by Product
8.3 Asia Pacific Cardiac Biomarkers by End User

9 Central & South America

9.1 Central & South America Cardiac Biomarkers by Countries
- 9.1.1 Central & South America Cardiac Biomarkers Sales by Countries
- 9.1.2 Central & South America Cardiac Biomarkers Revenue by Countries
- 9.1.3 Brazil
9.2 Central & South America Cardiac Biomarkers by Product
9.3 Central & South America Cardiac Biomarkers by End User

10 Middle East and Africa

10.1 Middle East and Africa Cardiac Biomarkers by Countries
- 10.1.1 Middle East and Africa Cardiac Biomarkers Sales by Countries
- 10.1.2 Middle East and Africa Cardiac Biomarkers Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
10.2 Middle East and Africa Cardiac Biomarkers by Product
10.3 Middle East and Africa Cardiac Biomarkers by End User

11 Company Profiles

12 Future Forecast

12.1 Cardiac Biomarkers Market Forecast by Regions
- 12.1.1 Global Cardiac Biomarkers Sales Forecast by Regions 2019-2025
- 12.1.2 Global Cardiac Biomarkers Revenue Forecast by Regions 2019-2025
12.2 Cardiac Biomarkers Market Forecast by Product
- 12.2.1 Global Cardiac Biomarkers Sales Forecast by Product 2019-2025
- 12.2.2 Global Cardiac Biomarkers Revenue Forecast by Product 2019-2025
12.3 Cardiac Biomarkers Market Forecast by End User
12.4 North America Cardiac Biomarkers Forecast
12.5 Europe Cardiac Biomarkers Forecast
12.6 Asia Pacific Cardiac Biomarkers Forecast
12.7 Central & South America Cardiac Biomarkers Forecast
12.8 Middle East and Africa Cardiac Biomarkers Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis
14.2 Cardiac Biomarkers Customers
14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
16.2 Author Details

Description

Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.
The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years.
There is a high demand for cardiac biomarkers due to their proficiency and the ability to provide accurate results. The number of clinical trials conducted for cardiac biomarkers is steadily increasing since manufactures, universities, and research institutes are focused on improving the efficiency and efficacy of the biomarkers. Cardiac biomarker manufacturers are increasingly focusing on R&D to perform several clinical trials to prove the effectiveness of the products and increase their consumer base. According to our industry research and analysis, the increase in number of clinical trials will be one of the key trends that will gain traction in the cardiac biomarkers market during the next few years.
North America leads the global market, owing to the high demand for cardiac testing, high CVD prevalence rate and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is growing at the fastest CAGR due to the modernization, increasing disposable incomes and rising affordability for the advanced cardiac treatments.
The global Cardiac Biomarkers market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cardiac Biomarkers market based on company, product type, end user and key regions.

This report studies the global market size of Cardiac Biomarkers in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cardiac Biomarkers in these regions.
This research report categorizes the global Cardiac Biomarkers market by top players/brands, region, type and end user. This report also studies the global Cardiac Biomarkers market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Abbott
Alere
F. Hoffmann-La Roche
Advanced ImmunoChemical
AgPlus Diagnostics
BG Medicine
BioLegend
bioMérieux
Bio-Rad Laboratories
BODITECH MED

Market size by Product
Troponin
CK-MB
Natriuretic Peptides - BNP and NT-proBNP
Myoglobin
Others
Market size by End User
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Cardiac Biomarkers market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cardiac Biomarkers market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cardiac Biomarkers companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cardiac Biomarkers submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Cardiac Biomarkers are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cardiac Biomarkers market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.